# Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

> **NCT02210715** · PHASE4 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 31 (actual)

## Conditions studied

- HIV
- Fatty Liver
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Isentress.
- **OTHER:** Continue usual antiretroviral therapy

## Key facts

- **NCT ID:** NCT02210715
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210715, "Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02210715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*